Results 31 to 40 of about 56,913 (295)

In vitro inhibitory effects of cepharanthine on human liver cytochrome P450 enzymes

Pharmaceutical Biology, 2020
Context Cepharanthine (CEP) extracted from the roots of Stephania cepharantha Hayata (Menispermaceae), has a range of therapeutic potential in clinical conditions.
Xunge Zhang, Ping Feng, Xinfu Gao, Bin Wang, Chunxia Gou, Ruimin Bian   +5 more
doaj   +1 more source

Generation of tetracycline-controllable CYP3A4-expressing Caco-2 cells by the piggyBac transposon system

Scientific Reports, 2021
Caco-2 cells are widely used as an in vitro intestinal epithelial cell model because they can form a monolayer and predict drug absorption with high accuracy. However, Caco-2 cells hardly express cytochrome P450 (CYP), a drug-metabolizing enzyme.
Moe Ichikawa, Hiroki Akamine, Michika Murata, Sumito Ito, Kazuo Takayama, Hiroyuki Mizuguchi   +5 more
doaj   +1 more source

Exposure to CYP3A4‐inducing and CYP3A4‐non‐inducing antiepileptic agents and the risk of fractures [PDF]

Pharmacoepidemiology and Drug Safety, 2011
ABSTRACTPurposeTo evaluate whether exposure to Cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4)‐inducing antiepileptics increases fracture risk compared to CYP3A4‐non‐inducing antiepileptics.MethodsWe performed a retrospective cohort study of initiators of antiepileptic agents using a UK medical record database (The Health Improvement ...
Hedi, Schelleman, John R, Pollard, Craig, Newcomb, Clyde E, Markowitz, Warren B, Bilker, Mary B, Leonard, Sean, Hennessy   +6 more
openaire   +2 more sources

CYP3A4*1G gene Polymorphism on Javanese People

, 2011
Most of drugs are metabolized by cytochrome P 450 (CYP) enzyme. Cytochrome P450 3A4 is the cytochrome that is involved in metabolizing more than 60% of all medicine used in human.
Kristin, Erna, Dwiprahasto, Iwan, Iwan Dwiprahasto, Erna Kristin, Em Sutrisna, Sutrisna, Em   +5 more
core   +2 more sources

Investigation of the interindividual variability in hepatic cytochrome P450 CYP3A4, association with CYP3A4*1B [PDF]

, 1999
grantor: University of TorontoIn this study, we determined the association of 'CYP3A4*1B' ('CYP3A4-V') to the large interindividual variability in hepatic CYP3A4.
Ciaccia, Antonio
core   +1 more source

Effects of genetic polymorphism of CYP3A4 and CYP3A5 on analgesic efficacy of postoperative intravenous analgesia with sufentanil in patients after laparoscopic surgery

Di-san junyi daxue xuebao, 2022
Objective To explore the differences of postoperative patient-controlled intravenous analgesia (PCIA) with sufentanil in the patients with different CYP3A4 and CYP3A5 genotypes after laparoscopic surgery. Methods According to CYP3A4 and CYP3A5 genotypes,
GU Li, ZHOU Li, LI Yongshuai, FENG Liyuan, CHEN Xingtong   +4 more
doaj   +1 more source

The EMA Qualification Opinion for CYP Inhibition-Mediated Drug-Drug Interaction Predictions: Implications for PBPK Credibility Assessment in the Era of ICH M15. [PDF]

Clin Pharmacol Ther
Clinical pharmacology and pharmacometrics teams are now being encouraged to implement the ICH M15 framework in drug development to support model‐informed decisions in regulatory submissions. Although model performance is an important component of model evaluation, regulatory confidence also depends on the intended context of use (CoU) and the ...
Rowland Yeo K, Neuhoff S, Hatley O, Gardner I, Brochot C, Bois FY, Jamei M.   +6 more
europepmc   +2 more sources

Characterization of Reference Materials for CYP3A4 and CYP3A5 [PDF]

, 2023
Pharmacogenetic testing for CYP3A4 is increasingly provided by clinical and research laboratories; however, only a limited number of quality control and reference materials are currently available for many of the CYP3A4 variants included in clinical ...
Chernova, Dilyara, Lisa V. Kalman, Mitchell, Matthew W., Ty C. Lynnes, van Schaik, Ron H.N., Jason Oliva, Caitlin A. Granfield, Cheranova, Dilyara, Granfield, Caitlin A., Jennelle C. Hodge, Broeckel, Ulrich, Amy J. Turner, Wang, Wendy Y., Wendy Y. Wang, Ann M. Moyer, Erin C. Boone, Oliva, Jason, Hodge, Jennelle C., Turner, Amy J., Lynnes, Ty C., Andrea Gaedigk, Gaedigk, Andrea, Dilyara Chernova, Boone, Erin C., Ron H.N. van Schaik, Reynold C. Ly, Ulrich Broeckel, Kalman, Lisa V., Matthew W. Mitchell, Moyer, Ann M., Ly, Reynold C.   +30 more
core   +1 more source

Frequency of CYP3A4*1B, CYP3A4*22 and CYP3A5*3 polymorphisms in the Croatian population

, 2022
Enzimi pod-porodice citokroma P450 3A (CYP3A) sudjeluju u metabolizmu oko 50% lijekova u kliničkoj primjeni. Najvažniji su enzimi CYP3A4 i CYP3A5, za koje je karakteristična interindividualna varijabilnost.
Petreković, Sandra
core   +1 more source

INFLUENCE OF THE CYP3A4 ISOENZYME METABOLIC ACTIVITY AND CYP2C19 GENE POLYMORPHISMS ON CLOPIDOGREL ANTIPLATELET EFFECT IN PATIENTS WITH ACUTE CORONARY SYNDROME UNDERGOING PERCUTANEOUS CORONARY INTERVENTION

Рациональная фармакотерапия в кардиологии, 2015
Aim. Carriership of CYP2C19*2 allelic variant and reduced CYP3A4 activity can affect the formation of clopidogrel’s active metabolite and, respectively, its antiplatelet effect.
K. B. Mirzaev, R. E. Kazakov, V. V. Smirnov, D. A. Andreev, D. A. Sychev   +4 more
doaj   +1 more source